Gabriela Constantin, M.D., Ph.D.  

  • Professor of Pathology and Immunology, University of Verona
  • Director, CSO and Co-Founder, VENETO Pharma
  • Director and Co-Founder, LEUVAS Therapeutics


Dr. Constantin is a recognized leader in neuroimmunology, neuroinflammatory disease, multiple sclerosis, Alzheimer's disease, and the role of leukocyte trafficking in neurological diseases.  She has made seminal contributions to the identification of key inflammation mechanisms in multiple sclerosis, epilepsy and Alzheimer's disease.  Drs. Constantin, Butcher, and Fabene made the initial discovery that seizures induce expression of vascular adhesion molecules and enhanced leukocyte-endothelial interaction, and that inhibition these interactions prevented BBB leakage, markedly reduced seizures, and prevented development of epilepsy. Dr. Constantin’s clinical insight connecting these results with the anecdotal reports of rapid reversal of long lasting uncontrolled epilepsy in MS patients treated with Tysabri.  She recently made a groundbreaking discovery in Alzheimer's disease research by demonstrating a role for neutrophil trafficking in Alzheimer's disease and demonstrated that blockade of neutrophil trafficking reduced amyloid accumulation, phosphorylated tau, microglial cell activation and prevented cognitive decline in animal models of AD.

Dr. Constantin received her M.D degree from the University of Milan and Ph.D degree from the University of Verona. She completed a residency in Neurology at the Policlinico Hospital, University of Milan. She received Rita Levi Montalcini Award and the first Prize of the European Charcot Foundation for her neuroimmunology studies and was nominated by the European Research Council as "outstanding female scientist" in 2012.


Selected Publications

1: Zenaro E, et al Neutrophils promote Alzheimer's disease-like pathology and cognitive decline via LFA-1 integrin. Nat Med. 2015

2: Angiari S and Constantin G. Regulation of T cell trafficking by the T cell immunoglobulin and mucin domain 1 glycoprotein. Trends Mol Med. 2014 Dec;20(12):675-84.

3: Angiari S,  et al. TIM-1 glycoprotein binds the adhesion receptor P-selectin and mediates T cell trafficking during inflammation and autoimmunity. Immunity. 2014 Apr 17;40(4):542-53.

4: Angiari S, Constantin G. Selectins and their ligands as potential immunotherapeutic targets in neurological diseases. Immunotherapy. 2013 Nov;5(11):1207-20.

5: Angiari S, et al. Regulatory T cells suppress the late phase of the immune response in lymph nodes through P-selectin glycoprotein ligand-1. J Immunol. 2013 Dec 1;191(11):5489-500.

6: Fabene et al, (2008) A role for leukocyte-endothelial adhesion mechanisms in epilepsy.  Nat Med. 2008 Dec;14(12):1377-83